Increasing participation in fecal screening tests is a major challenge in countries that have implemented colorectal cancer (CRC) screening programs.
C olorectal cancer (CRC) is the third most frequent cancer worldwide, 1,2 accounting for 694 000 deaths in 2012 and was the second most lethal cancer after lung cancer. 1, 2 The five-year survival rate depends on the stage at diagnosis: the rates for the localized stage, local extension to the lymph nodes, and the metastatic stage in 2013 were 90.1%, 70.8%, and 13.1%, respectively. 1,2 Screenings based on sigmoidoscopy or fecal tests are associated with a decreased 10-year mortality rate. 3 Many countries have implemented CRC screening based on fecal immunochemical tests (FIT). 4 In France, asymptomatic individuals aged 50 to 74 years receive a postal invitation to consult their GPs to obtain a FIT testing kit. The GP refers patients with a positive test result to a gastroenterologist for a colonoscopy. Colonoscopy screening is reserved for symptomatic or high-risk individuals on the basis of family history, and GPs serve as gatekeepers for access to colonoscopy. Patient participation in CRC screening is a major challenge. 5 National participation in CRC screening in France was only 29.8% from 2013 to 2014, far below European goals. 6 In 2015,
the French national health system switched from the fecal occult blood test to FIT because of its the higher sensitivity and specificity. 7 Prior work has examined patient-focused strategies to increase participation in CRC screening, such as postal mailing of screening kits, written or telephone reminders, and tailored navigation. 8, 9 However, research has not sufficiently explored whether reminders directed to GPs increases patient participation. [8] [9] [10] The objective of this study was to evaluate whether providing GPs with a list of their patients who were at average risk of CRC but had yet to undergo CRC screening would increase patient participation compared with either informing GPs generically about regional-level CRC screening rates or maintaining usual care.
Method

Study Design and Participants
The study was a cluster randomized clinical trial with 3 parallel groups conducted from July 14, 2015, to July 14, 2016, in 2 areas on the French west coast. General practitioners were clustered within practices to avoid contamination bias stemming from shared tracking mechanisms and communication among GPs within a practice. The study protocol was approved by the human subjects ethics committee of Rennes. A waiver of individual participant-level informed consent was provided by the ethics committee. The full protocol is included in the Supplement.
General practitioners in the Loire-Atlantique and Vendée areas with at least 100 patients older than 16 years on their patient list according to the national health care insurance system were eligible. In October 2014, information about the study was sent to 1501 GPs, who could opt out of participation by contacting the research team.
Since 2015, FIT rather than fecal occult blood test screening has been used in France. FIT screening every 2 years is recommended for patients at average risk of CRC, based on (1) being between the ages of 50 years and 74 years; (2) having neither a personal history of CRC or adenoma larger than 1 cm nor a family history of CRC; and (3) manifesting no symptoms of CRC. Colonoscopy screening is reserved for patients at elevated risk of CRC corresponding to approximately 15% of the population aged 50 years to 74 years.
In the French CRC screening program, local health associations invite patients to participate in the screening if they are eligible for and have yet to complete their FIT screening in the preceding 24 months. The invitation advises them to obtain a FIT kit during a physician's visit because kits are not mailed directly to patients. Each patient is asked to mail the completed FIT kit with a stool sample in a prepaid envelope. Test results are sent to the patient, the GP, and the local public health association. Patient participation is tracked at 3 and 6 months after the invitation letters are mailed. Patients who have not returned a FIT screening within 3 months are defined as nonadherent. Nonadherent patients may receive as many as 2 written reminders: the first at 3 months and the second at 6 months after the first invitation. Patients with a positive test result are referred to gastroenterology for colonoscopy. Local health associations maintain a tracking system that integrates information from the national health insurance system, FIT laboratories, pathology laboratories, hospital information systems, gastroenterologists, GPs, and the cancer registry, in accordance with European guidelines. 6 French GPs receive financial incentives based on the number of CRC screening tests their patients complete, which for the study period was €60 (US $70) for the first 10 completed FIT tests up to an annual maximum incentive of €1030 (US $1205) per year. Our study focused on the subset of the GP's average-risk patients who had not completed FIT testing within the 3 months of receiving the first CRC screening invitation. Patients were eligible to participate in our study if they (1) had not returned the FIT and were candidates for the 3-month reminder letter as of
Intervention and Control Procedures
In July 2015, General practitioners were randomly assigned to 1 of 3 groups (Figure) . To avoid contamination bias, the unit of randomization was by medical practice rather than by GP. Randomization was computer generated and stratified over the 2 geographic areas.
The GPs in the patient-specific reminders group were mailed their first list of patients a few days after the study began (July 2015) and a second updated list was mailed in November 2015. They were informed that they could request another copy if they lost the original list. The GPs were advised of tips that could help them follow up with patients: integrate informatics reminders with each patient file, ensure that medical practice secretaries recontacted each patient on the list, or place the list on their desks. There was no specific requirement, and the GP had the freedom to decide how to use the information. General practitioners in the generic reminders group received CRC screening rates in the local administrative district. They received neither a list of their patients who were nonadherent nor specific instructions or suggestions on how to encourage patients to complete the screening. General practitioners in the usual care group received no information about CRC screening rates. Although the screening program offers a pay incentive to physicians whose patients complete the screening, this incentive was not part of the study, did not change over the study period, and did not differ across groups.
Study End Points
The primary end point was patient participation in FIT CRC screening 1 year after the 3-month reminder had been mailed. Participation was calculated as the proportion of patients who had completed FIT screening among all average-risk patients eligible for CRC screening, which was determined at the beginning of the study. The number of CRCs identified as a result of the FIT screening was also a primary end point. However, these data are not yet available from the national cancer registry.
11,12
Secondary end points included screening participation rates in subgroups based on patient characteristics including sex, age, low socioeconomic status (defined as an annual income < €8593 [<US $10 054] for an individual or < €12 889 [US $15 080] for a couple), and presence of a severe chronic disease (defined using a list of 30 severe chronic diseases leading to high costs for patients). 13 The economic costs related to each reminder strategy was a planned secondary end point, but these data are not yet available and are not reported in this article. Post hoc outcomes analyzed whether patient participation to FIT screening was linked to characteristics of the GPs (sex, age, practice location, and activity).
Data Collection
Data regarding patient participation were stored by regional public health authorities, based on recommended procedures implemented for general care. 6 As reported previously, local associations overseeing the screening program used a dedicated computerized database that allowed for the collection of data from all partners involved (national health insurance systems, the FIT laboratory, pathology laboratory, hospital information system, gastroenterologists, GPs, patients, the regional cancer registry). Patients who completed the FIT within a year of receiving their first reminder were classified as adherent, whereas other patients were classified as nonresponders. Based on this classification, no data were missing. Patient and GPs' characteristics were extracted from the national health care insurance database. This data extraction procedure allowed for complete collection of data related to patient and GPs' characteristics.
Statistical Analysis
The objective of this analysis was to be as exhaustive as possible in the recruitment of GPs to avoid selection bias. We estimated that at least 1300 GPs would participate among all those eligible, corresponding to 433 in each group. Based on this recruitment, we assumed that participation in CRC screening would be at least 12% higher in the patient-specific reminders group than in the other groups (absolute mean difference, 67% vs 55%; estimated SD, 0.61; bilateral α risk, 5%; statistical power, 80%). Participation in the usual care group was estimated at 55% using the following data. During 2012 and 2013, participation in the fecal occult blood test screening was equal to 38.2% in Western France based on rates measured by the regional public health authority. Based on a literature review, 9 we hypothesized that participation in CRC screening would be higher after introduction of the FIT (vs the fecal occult blood test). International studies concluded that using the FIT rather than the fecal occult blood test significantly increased participation from an odds ratio (OR) of 0.86 to 2.14 (median, 1.44).
7,14-18 Thus, the study power was based on a projected participation rate of 55% (38.2% × 1.44).
The significance threshold was P < .05. Testing was 2-sided. The study design avoided having missing data. The modified intention-to-treat method was applied and included all randomized GPs. General practitioners who had changed their eligibility criteria (practice cessation, practice reorientation, address modification, or death), either before the randomization or during the study, were excluded from the analysis.
For the primary end point, the GP was the statistical unit of analysis. Each GP was characterized by the ratio of participation of their patients 1 year after participation invitations were sent. This ratio was defined as the number of patients who sent back their FIT screen to the number of patients who at the beginning of the study had not sent back their FIT screen (continuous variable). The results were confirmed with a mixed-model regression analysis adjusted for all GP characteristics as shown in Table 1 . Medical practices were considered a between-unit random effect. The randomized group was considered a fixed effect. The random effect accounted for correlations among GPs in the same practice. A global analysis of variance test was performed to compare participation among all groups. If the null hypothesis was rejected, then comparisons between the usual care group with the others would be performed.
Patient factors associated with participation in CRC screening (prespecified analysis provided in the protocol) were assessed with a mixed-general linear model for which the Y was the status of each patient depending on whether he/she participated (logical variable). The patient was the statistical unit. In this model, the GP was considered a withinunit random factor, and the variables were patient characteristics. No selection procedure was performed.
In post hoc analyses, GP factors associated with patient participation in the FIT screening were assessed by a mixedgeneral linear model for which the Y predicted was the percentage of participation of each GP (continuous variable). General practitioners were the statistical unit. Additionally, medical practices were considered between-random effects, and the fixed variables were GP characteristics. No selection procedure was performed.
Analyses were performed using R 3.20 statistical software. The GLIMMIX and the Mixed Procedures of SAS version 9.4 (SAS Institute Inc) were used to estimate the models including the random effects.
Results
Participants
A written study description was mailed to 1501 GPs identified as eligible for the present study, located in 801 medical practices. One GP opted not to participate (Figure) . Between mailing the study introductory letter in October 2014 and randomization in July 2015, 18 GPs were excluded because of practice cessation, practice reorientation, address modification, or death. Another 36 GPs were excluded after the randomization for the same reasons. Among 1482 randomized GPs (mean age, 53.4 years; 576 women [38.9%]), 1446 completed the study and were included in the analysis, 496 of whom were randomized to the patient-specific reminders group; 495, to the generic reminders group; and 455 to the usual care group. 
Participation in FIT Screening (Primary End Point)
At 1 year, the mean patient participation per GP was 24.8% (95% CI, 23.4%-26.2%) in the patient-specific reminders group, 21.7% (95% CI, 20.5%-22.8%) in the generic reminders group, and 20.6% (95% CI, 19.3%-21.8%) in the usual care group, with between-group differences of 3.1% (95% CI, 1.3%-5.0%) for patient-specific reminders vs generic reminders, 4.2% (95% CI, 2.3%-6.2%) for patient-specific reminders vs usual care, and 1.1% (95% CI, −0.6% to 2.8%) for generic reminders vs usual care ( Table 3) .
Patient Factors Related to Participation (Secondary End Points)
Patients with a low socioeconomic status and patients who had a chronic disease were less likely to complete the FIT screening ( Table 4) .
GP Practice Characteristics Related to Participation (Post Hoc Analysis)
The following GP practice characteristics were associated with greater participation in FIT screening of patients who were nonresponders at the beginning of the study: younger physicians, GPs receiving a greater number of medical visits per year, and GPs who had fewer nonresponders on their list at the beginning of the study ( Table 5) . 
Discussion
In this open, randomized 3-group study, providing GPs with a list of patients who were nonadherent to CRC screening was associated with a modest increase in FIT participation compared with providing GPs with generic reminders about regional CRC screening rates or providing no reminders. These results were consistent across statistical models considering either GPs or patients as the statistical unit after adjustments for GP or patient characteristics. The analysis demonstrated a significant absolute difference of 4.2% between the patient-specific reminders group and usual care group, even though the statistical plan was designed to detect an anticipated difference of more than 12%. The reason this difference could be detected is that the standard deviation of the study (15%) was lower than the value included in the protocol (61%). The target of this large randomized clinical trial (RCT) was the GP rather than the patient. In most strategies proposed by policy makers, interventions are designed to directly influence patients. [8] [9] [10] In a previous review focusing on patient participation in CRC screening, Rat et al e Defined as an annual income lower than €8593 (US $10 054) for an individual or lower than €12 889 (US $15 080) for a couple.
f Defined using a list of 30 severe chronic diseases leading to high costs for patients. However, these interventions were voluntary; thus, generalizing at a population level might be difficult. According to GPs, lack of time is one of the primary barriers limiting wider promotion of CRC screening during consultation.
13
26,27
Based on a large RCT, these study findings present stronger evidence than a "before vs after" study, 28 a crosssectional study, 29 orasmallRCT, 30 and results confirm the conclusions of a previous smaller trial that targeted physicians.
31
Participation in CRC screening increased in the patientspecific reminders group compared with the usual care group. However, the statistical plan was based on the assumption that the participation rate would be higher in all randomized groups because of the switch from the older fecal occult blood test to the FIT in France at the beginning of 2015.
7,14-18 One problem was that French authorities decided to interrupt postal mailing of the tests to patients due to the expense of the FIT kits. This modification to the screening program aimed to avoid wasting tests but diminished the positive effect of patientspecific reminders. Piette et al 32 demonstrated that interruption of mailing kits to patients decreased the participation rate from 45% to 28%. In this study, patient participation was higher for younger physicians, possibly because these GPs may have greater concerns about public health and screening procedures. 26 Although lack of time has been widely reported as a main barrier to GP involvement in cancer screening, 26,27 this study presents original findings. A hypothesis was that physicians with more visits would pay more attention to acute disease and could neglect preventive procedures due to these time constraints. In contrast, the study results show that CRC screening rates were higher for GPs who have busier practices, regardless of the randomized groups. The reason is unclear and requires further investigation. As French authorities have introduced a pay-for-performance grant related to cancer screening, a possible hypothesis is that some busy physicians could also be more sensitive to financial incentives.
33
Having a short list of nonadherent patients increased participation rates among nonresponders. One explanation is that targeting nonresponders was easier for GPs who received a shorter list of patients. However, GPs who had shorter lists were probably also the most motivated.
This study provides insight into the factors related to patient participation in CRC screening. Some of these findings are consistent with those of previous studies. Patients with low socioeconomic status had lower participation rates.
34,35 Findings regarding patients having a chronic disease provide insight into the impact of comorbidities. Gonzalez et al 36 reported that patients who were diagnosed at more advanced stages were more likely to have comorbid diseases. General practitioners may not focus their attention and energy on cancer screening because of concerns about other health issues.
Perhaps patients who are not concerned about cancer screening also demonstrate a lack of time for health and prevention in general. Thus, GPs' greater involvement with these populations may first affect other health issues consistent with risk assessment and disease prevalence. The literature presents conflicting information regarding whether patient age and sex affect participation in CRC screening.
37-39 Recent publications have reported lower participation among younger individuals and male patients 37, 39 but these findings were not confirmed in our study. This study has several strengths. First, the inclusion of 1446 GPs and 31 229 patients represents, to our knowledge, the largest randomized study focusing on CRC screening participation.
9 Second, the generalizability of these results is important for the following reasons. The intervention was not expensive and did not need to be voluntary. Almost all GPs in the 2 geographic areas were included and participated. Thus, selection bias was not a concern. The effects of the intention-to-treat procedure mean that the patientspecific reminders increased CRC participation regardless of GP attitudes. Third, the increase in patient participation concerned only patients who were not adherent at the beginning of the study, whereas other studies assessed a general participation rate. Fourth, the observed effects might continue to increase if patient-specific reminders were implemented in usual care: (1) the study reported patient participation after a 12-month follow-up, but not all nonadherent patients had a medical consultation during this period, and (2) a hypothesis is that the positive effect might continue to increase in the patient-specific reminders group if an updated list was provided yearly (whereas participation in the usual care group should not be modified).
Limitations
The study also has limitations. First, the main limitation is the small magnitude of the increase in participation. Increasing participation by only 4% (absolute participation increase) might be regarded as disappointing. Second, the design of this study does not allow a clear report of how providing patientspecific reminders to the GPs positively affects CRC screening participation. A hypothesis is that the physicians concentrated their efforts on these nonadherent patients and customized their communication to the personality and characteristics of each patient to enable shared decision making. 8, 40 Third, the generalizability of the study findings might depend on the national setting: generating a list of nonresponders requires good data and the resources to create the list. Even in practices with electronic health records, this might not be possible because tests and procedures are sometimes performed outside of the clinic setting and because results are often entered in ways that cannot be captured electronically.
Conclusions
Providing French GPs caring for adults at average risk of CRC with a list of their patients who were not up-to-date with their CRC screening resulted in a small but significant increase in patient participation in FIT screening at 1 year compared with patients who received usual care. Providing GPs with generic reminders about regional rates of CRC screening did not increase screening rates compared with usual care. 
Analysis objectives
To demonstrate that disseminating to general practitioners (GPs) a nominative list of some of their patients who did not participate in the colorectal cancer (CRC) screening, allows increasing the participation rate in the organized screening and decreasing the number of cases of cancer diagnosed outside the organized screening.
Estimated number of cases
GPs practicing in the French departments 44 and 85, having more than 100 patients in their patient list (regardless of the age) will be randomized into 3 groups. About 1,300 physicians.
Main selection, inclusion, non-inclusion and exclusion criteria
Inclusion criteria: GP having more than 100 patients in their patient list, practicing in the Loire Atlantique or Vendée geographic areas.
Non-inclusion criteria: GP who met the inclusion criteria but expressly refused to participate in the study.
Target indication
Participation rate of patients eligible for the CRC organized screening and number of cancers detected in the organized screening.
Statistical analyzes
A prioritized test strategy is used to test the 3 nested hypotheses: H0: No difference in patient participation rate between the 3 arms If this hypothesis is rejected, the second H0 will be tested: no difference in the number of detected cancers between the 3 arms If the previous hypothesis is rejected, the third H0 will be tested: no difference in the "number of detected cancers/total number of occurrences of cancer" ratio between the 3 arms INTRODUCTION ................................................................................................................................... .... 7
LIST OF ABBREVIATIONS
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INTRODUCTION
In France, colorectal cancer (CRC) is the third and second most common cancer respectively in men and women. The standardized incidence rate is 37.7/100,000 in men and 24.5/100,000 in women. In France, a controlled study in the general population has shown a 16% reduction in CRC mortality after 11 years of follow-up, under certain organizational screening conditions CRC screening is coordinated by the "CAP Santé Plus 44" structure for organized cancer screenings for Loire Atlantique and by the "Audace" management structure (MS) for Vendée. As in the rest of the national territory, CRC screening is thus organized and coordinated with a direct invitation sent to patients by these organizations, so that CRC screening only slightly involves GPs. Several years after the implementation of this program, a strong limit of the tested screening is the high rate of patients who did not participate, and this despite numerous information campaigns targeting the general public.
In the literature, several authors have shown that the counseling provided by a GP could improve patient adherence to medical care.
Our project aims to assess the impact of the dissemination to GPs of a nominative list of their patients who did not participate in the CRC organized screening.
In their usual practice, GPs have no explicit feedback enabling them to determine whether a patient is up to date in his/her screening at a time t. We assumed that providing simple information to GPs in the form of an edited nominative list will help them to identify, among their patients eligible for the CRC organized screening, those who have not yet participated. This list could help them to more efficiently solicit pre-identified patients.
This change in practice is expected to increase the participation rate of their patients in the organized screening and under this assumption, increase the "number of detected cancers/total number of cancers reported to the cancer registry" ratio.
S R
CRC is a malignant tumor of the colonic or rectal mucosa.
In 2011, the number of new cases of CRC was estimated to be 40,500 in France. This is the third cancer in terms of frequency and the second in terms of cancer mortality.
An early detection results in a decrease in mortality and improves quality of life, by avoiding aggressive treatments to patients with advanced stages.
In 2009, the CRC organized screening has been generalized to the entire French territory and involves 50-74-year old adults with no specific risk factors for CRC. GPs are the most likely to convince their patients to perform the test. Indeed, an experience from the pilot departments showed that 85% of tests provided by GPs were performed by patients versus 15% in case of direct mailing. Meanwhile, the first cause reported by patients who did not participate in the screening is that their physician did not discuss it with them.
That is why APs are intended to be at the center of this approach, in direct contact with the concerned population.
Currently, they are the first to provide the test, or to explain to patients that they are not concerned (depending on their history, the presence of alert symptoms and potential colonic explorations previously performed).
GPs also report to the management structure the subjects to be excluded from the screening program, to avoid inappropriate reminders.
GPs also provide advice and explanations on the practical realization modalities, which allows reducing the number of incorrect and therefore uninterpretable tests.
In case of a positive test, GPs are responsible for convincing their patients to perform colonoscopy and organizing it (10-15% of patients do not perform it).
Finally, physicians are in the front line to manage the difficult situations of false negatives and interval cancers, cancers occurring despite a negative test, between two screenings, and false positives leading to perform a colonoscopy without discovery of lesions likely to cause complications and anxiety.
Passing by GPs therefore has several advantages and allows improving the quality and efficacy of the approach. The new immunological test allows detecting lesser bleedings than those detected with the guaiac test. Various studies have shown that this immunological test would help to detect 2 to 2.5 times more cancers and 3 to 4 times more advanced adenomas than the current test, while performing 2 times fewer colonoscopies. The gains in sensitivity associated with the immunological test would be more relevant to precancerous lesions, which has an additional interest in the context of a preventive approach (cancers are prevented and no longer treated).
The experiment conducted in two departments using the OC Sensor® test has shown a 71% detection rate of Tis stage (in situ) and stage I and II cancers versus 55% for the guaiac test.
The immunological test is also easier to perform than the guaiac test: a single stool sample against six currently, a more reliable sampling technique that limits stool handling, and an enhanced test ergonomics, which is likely to improve the test acceptability by the population.
In addition, the automated reading of these tests ensures both a better reliability and reproducibility of the test revelation procedures investigating the presence of blood in the stools, which enhances the quality assurance of the reading. The campaign for the provision of However to our knowledge, no randomized study of the factors influencing patient adherence to the organized screening or assessing the role of the GP has been conducted.
The GP would be the most important factor in patient adherence to the screening. It is necessary to identify the factors that may modify the physician behavior to encourage their patients to adhere to the screening.
One of the approaches is purely financial, a revaluation of this specific procedure may be envisaged, but to be effective, the revaluation threshold may be prohibitive if it is based on a cost/effectiveness ratio.
Another approach is to facilitate their work. We assume that if 
B B
The organized screening allows detecting earlier colorectal cancers. An increase in quality of life and survival rate has been shown in screened patients compared to patients whose cancer has been diagnosed.
The CRC organized screening has been extended to the whole of France due to a proven collective benefit in terms of care costs, survival and quality of life.
R
Since this study only involves the transmission of information, GPs participation in this study will have no direct impact on the management and will not involve any risk for their patients.
In addition, since the organized screening is extended to the whole of France, the cost for producing and disseminating a nominative list for GPs presents no economic risk.
National and international assessments have shown a collective benefit for the CRC organized Some local structures in charge of CRC screening organization send non-nominative information control panels to GPs in order to raise awareness to CRC screening. For measuring the effect of a nominative list, it is important to have 2 control groups, one receiving no information, the other receiving a control panel of aggregated data.
P
The primary endpoint is composed of 3 nested criteria. The 3 hypotheses are tested in a predetermined order. The second hypothesis is only tested if the null hypothesis of the first test has been rejected at the two-sided alpha risk threshold of 5%. The third hypothesis is only tested if the null hypothesis of the second test has been rejected at the two-sided alpha risk threshold of 5%.
There are 3 prioritized primary objectives. This strategy allows maintaining an alpha risk of 5% throughout the prioritized procedure.
-First primary endpoint: participation rate in the organized screening. It is calculated as the "number of patients who participated in the organized screening / number of patients eligible for the organized screeening" ratio.
-Second primary endpoint: number of CRCs detected through the organized screening.
V8 dated 05/11/2013 Page 15 of 41 -Third primary endpoint: "number of CRCs detected through the organized screening/number of diagnosed cancers in patients eligible for the organized screening" ratio. All cancers not detected using the test, including interval cancers and cancers occurring in patients exempted from testing due to clinical signs suggestive of CRC will be considered as diagnosed cancers.
The rationale for the presence of the second and third primary endpoints is based on the different power of statistical tests used to compare means and proportions.
S
To estimate the cost for disseminating a nominative list of patients who did not participate in the organized screening.
To identify the factors (patient characteristics) associated with the non-adherence to the organized screening.
To identify the factors (patient and GP characteristics) improving the efficacy of the nominative list in paper form.
Costs for disseminating a nominative list.
Patient socio-economic and demographic characteristics.
GP practice characteristics.
"
Descriptive analyzes
They will focus on all the variables collected and will be performed for the 3 randomization groups.
The quantitative data will be described as the mean, median, standard deviation, 95% CI of the mean, minimum and maximum values, number of missing values, number of non-exploitable values.
The qualitative data will be described as proportions with their 95% CI for each group. The proportion of missing values, proportion of non-exploitable values will also be described with their 95% CI.
Explanatory analyzes
An exploratory analysis of patient and GP socio-demographic factors and GP type of exercise will be carried out to identify the other factors that may explain a better participation rate in the organized screening in the target population.
Comparative analyzes
A generalized linear model (GLM) will be used to compare the 3 randomized groups stratified according to the department.
The ITT (Intent-to-treat) will be applied.
Medico-economic study
A comparative analysis of the direct costs in the 3 arms will be carried out:
Comparisons will be made using ratios: cost per completed organized screening, cost per detected cancer.
R O
Open-labeled, cluster-randomized study with 3 parallel arms stratified on two departments (Loire-Atlantique and Vendée).
GPs are the statistical unit. Medical practices are the clusters to avoid a contamination bias due to the proximity of physicians and patients. Medical practices may be composed of one or more GPs practicing at an identical mailing address (group practices).
The first arm (A) receives 2 documents: a list reporting non-participating patients: patients eligible for the organized screening who did not complete it in the previous 24 months (document 1) + a control panel of aggregated data on the CRC organized screening of their canton and department (document 2).
The second arm (B) only receives document 2.
The third arm (C) receives no additional document. 
"
Refer to Appendix 1
STUDIED POPULATION P
The study is conducted in the 2 departments of Loire Atlantique and Vendée.
All GPs with more than 100 patients (living or not in the departments 44 and 85) in their patient list will be included in the study.
The list of eligible GPs in the 2 departments (44 and 85) will be provided by the Healthcare Insurance system services.
Eligible patients will be patients 1) belonging to the target population of the screening, 2)
belonging to the patients list of one of the participating GPs, 3) minus the patients excluded from the CRC screening for medical reasons.
R
To ensure statistical robustness to the results of the study, GPs must be partially blinded. They will therefore be semi-blinded, because they will not be aware of the groups that are compared. GPs will only be informed of the conduct of a study assessing cancer screening (through a personally sent form). The statistical unit assessed is the GP, the intervention is conducted on the physician and not on the patient. In order to prevent any change in GP practice regarding the screening of eligible patients, the randomization group will not be notified.
Patients whose data are collected by the cancer registry are informed of the transmission of information to the registry during their medical pathway for cancer management. Patients are informed by the physican(s) who manage them.
Patients are also informed of the exchange of data between the registry and the local structure in charge of CRC screening organization. The cancer registry is responsible for reminding the obligation of information to physicians in contact with patients.
In the context of the IDLN colorectal study, since the intervention of GPs on patients regarding the screening approach is the subject of the scientific assessment, and not patients themselves, no information shall be transmitted to patients about how the data will be used. Patients should rather be considered as a measurement or an indicator in the context of this study as is the number of patients consulting in a medical practice for example. In addition, informing patients that their physicians will participate may modify their behavior, which would significantly bias the study.
I
GPs practicing in Loire-Atlantique or Vendée who have at least 100 different patients (regardless of age) in their patients list are included in the study.
Definition of patients meeting the assessment criterion: included patients aged 50-74 years minus patients with medical exclusions from the organized screening whose GP is included.
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GPs who explicitly stated that they did not want to participate in the IDLN study. Knowing the name of patients who did not participate in the organized screening would help GPs to immediately identify non-participating patients and to directly discuss with them during their subsequent consultation.
It would be a useful tool for GPs who will not have to search for these patients in their records.
The information transmitted to the patients is thus less impersonal. A much stronger impact than that observed with a simple reminder by mail is expected on patient behaviors with respect to the organized screening.
In the absence of this concrete information transmitted to GPs, the current development of medical software and the organization of practice functioning do not allow physicians to be alerted or reminded concerning the follow-up of patients who do not consult.
Regarding patients who consult, such an information on the follow-up is often updated, but the quality of the follow-up is impacted by the interference of multiple solicitations of the consultations over time, so that the follow-up could be improved by allowing GPs to waste less energy and time to simply retrieve the information.
From the perspective of local structures in charge of CRC screening organization:
Local structures in charge of CRC screening organization manage nominative lists of patients as part of their usual mission. In this study, the name of the GP of the patients (provided by the Healthcare Insurance medical service) will be associated in order to provide a useful information to these GPs.
This joint information stops at the end of the study.
From the perspective of the registry:
The data transmitted from the registry to the local structures in charge of CRC screening organization are currently subject to an authorization from the National Commission "Informatics and Liberties" for patients who have participated in the organized screening. A specific authorization is requested in the context of this study for the transmission of nominative individual data of CRC cases diagnosed outside the organized screening for each department. Study-specific data will include for each patient: the name and address of their GPs, whether they suffered from a chronic disease, whether they benefited from reimbursement facilities associated with a low economic status: universal mutual coverage (CMU) or Supplemental Health Insurance Access (SHIA).. The number of detected or diagnosed cancers for each GP included in the study will be derived from the detailed individual data processed by the registry and local structures in charge of CRC screening organization.
IDLN COLORECTAL Study Protocol
" "
Name Approximately 1,300 GPs will be included. These 1,300 GPs will enable to achieve a power of 80% and a two-sided alpha risk of 5% to show a 12% difference between the experimental arm A and the 2 other control arms.
E
The two-sided alpha risk is set at 5%.
Eligible GPs in the 2 departments who will not refuse to participate in the study will be included.
R
The randomization will be centralized, stratified on the department. Upon receipt of the nominative lists of patients with their GP, the local structures in charge of CRC screening organization will first group the GPs according to their address. The practices will be coded according to their address by the local structures in charge of CRC screening organization, and then sent to the coordinator who will perform the randomization. 
N C I L CNIL
An authorization application file will be requested to the CNIL in two steps: . Transmission of the CCTIRS form to request for an opinion.
. The favorable opinion of the CCTIRS will allow sending the authorization application dossier to the CNIL. The specific circumstances of the study require the blinding of patients eligible for the CRC organized screening. Based on a methodological justification requiring the total blinding of patients whose computerized data will be the subject of a change of purpose (from an initial epidemiological purpose to a secondary scientific purpose), Nantes University Hospital will request to the CNIL an exemption from the requirement to disclose information.
"
A two-step statistical analysis is performed according to the receipt of the data. The final analysis will be performed 2 years after the beginning of GP inclusions, i.e. in 2016.
I A
The investigators will authorize and facilitate any inspection or audit requested by the National Institute for Cancer (INCa), the study sponsor or any competent authority (CNIL or Health Ministry). 
N
Given the large number of patients in the target population and in order to ensure the blinding procedure, an exemption from the requirement to disclose information to patients regarding the use of their data will be requested.
The organized target population includes patients aged 50-74 years having their GP in one of the two departments of Loire-Atlantique or Vendée, i.e. several tens of thousands of patients.
E
Since this research protocol does not fall within the scope of the French Comité de Protection des Personnes, it will be submitted to an IRB ethics committee for ethical opinion.
P
Any substantial modification of the protocol will be the subject of an update with a new date of protocol version. 
F I
This study is funded through the 2012 call for tenders of the French National Institute for Cancer (INCa).
R
A copy of the publication will be provided to Nantes University Hospital, and the study sponsor should necessarily be cited. The authors will be determined based on their contribution to this study. The coordinating investigator establishes the author list. 
